Antineoplaston Therapy in Treating Patients With Colon Cancer

Last updated: July 9, 2013
Sponsor: Burzynski Research Institute
Overall Status: Trial Not Available

Phase

2

Condition

Colon Cancer

Colorectal Cancer

Rectal Cancer

Treatment

N/A

Clinical Study ID

NCT00003486
BC-CO-3
CDR0000066524
  • Ages > 18
  • All Genders

Study Summary

RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.

PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating patients with colon cancer.

Eligibility Criteria

Inclusion

DISEASE CHARACTERISTICS:

  • Histologically confirmed adenocarcinoma of the colon that is unlikely to respond to existing therapy and for which no curative therapy exists

  • Measurable disease by MRI or CT scan

  • Metastatic or unresectable disease

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Karnofsky 60-100%

Life expectancy:

  • At least 2 months

Hematopoietic:

  • WBC at least 2,000/mm^3

  • Platelet count at least 50,000/mm^3

Hepatic:

  • Bilirubin no greater than 2.5 mg/dL

  • SGOT/SGPT no greater than 5 times upper limit of normal

  • No hepatic failure

Renal:

  • Creatinine no greater than 2.5 mg/dL

  • No renal failure

Cardiovascular:

  • No chronic heart failure

  • No uncontrolled hypertension

Pulmonary:

  • No serious lung disease, such as chronic obstructive pulmonary disease

Other:

  • Not pregnant or nursing

  • Fertile patients must use effective contraception during and for 4 weeks after study participation

  • No active infection

  • No serious malabsorption syndromes

  • No other serious concurrent disease

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • At least 4 weeks since prior immunotherapy and recovered

Chemotherapy:

  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

Endocrine therapy:

  • Concurrent corticosteroids allowed

Radiotherapy:

  • At least 8 weeks since prior radiotherapy and recovered (patients with multiple tumors may be admitted earlier)

Surgery:

  • No prior extensive stomach or intestinal surgery

Other:

  • Prior cytodifferentiating agent allowed

  • No prior antineoplaston therapy

  • No other concurrent anticancer therapy

Study Design

Study Start date:
Estimated Completion Date:

Study Description

OBJECTIVES:

  • Determine the antitumor activity of antineoplastons A10 and AS2-1 in patients with adenocarcinoma of the colon by determining the proportion of patients who experience an objective tumor response.

  • Evaluate the adverse effects of and tolerance to this regimen in these patients.

OUTLINE: This is an open-label study.

Patients receive gradually escalating doses of oral antineoplaston A10 and oral antineoplaston AS2-1 6-7 times a day. If the patient has not achieved a partial or complete response after 3-4 months of treatment, the investigator may discontinue treatment. Patients with stable disease may continue to receive treatment until disease progression or unacceptable toxicity is observed.

Tumors are measured every 4 months during the first 2 years, then every 6 months during years 3 and 4, and yearly during years 5 and 6.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.

Connect with a study center

  • Burzynski Clinic

    Houston, Texas 77055-6330
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.